AU · rank #15 · 2026-10-21
IOVA
NASDAQ · $6.73B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.336 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.09 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 5 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.206 |
| Analyst upside Consensus target $14.40 | +1.3% |
| Momentum acceleration 3-month minus 12-month momentum. | +132.75% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.40 |
| Gross margin TTM | +48.4% |
| 52w high | $15.30 |
| Market cap (USD) | $6.73B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Iovance Biotherapeutics is the only company with an FDA-approved commercial TIL therapy (Amtagvi) for advanced melanoma, generating ~$400M annualized revenue through a centralized 32-day manufacturing process across ~100 authorized treatment centers.
Rationale
All 5 upward EPS revisions in 30 days show 100% agreement, analyst targets are being raised (4 in 30 days) against a strong 18.4% earnings surprise and 66% YoY revenue growth, validating that consensus is still catching up to Amtagvi's commercial ramp.
Material risks
- 1Revenue is entirely concentrated in previously treated advanced melanoma, and slower treatment-center activation, reimbursement friction, or patient-referral bottlenecks could stall the ramp before IOVA reaches profitability — the $303.7M cash runway to mid-2028 leaves little margin for a commercial miss.
- 2Obsidian's OBX-115 and other outpatient biopsy-based or engineered TIL platforms could erode Iovance's manufacturing-complexity moat if they demonstrate comparable efficacy with a simpler logistics profile, particularly in the first-line melanoma and NSCLC indications where IOVA has no approved product yet.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.